Kymera Therapeutics, Inc. Common Stock (KYMR) Stock Price, Quote & AI Analysis

Live KYMR stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Kymera Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Kymera Therapeutics, Inc. Common Stock (KYMR), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

KYMR
Kymera Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
91.400000
High
93.640000
Low
89.060000
Volume
1,058,186
VWAP
-
Market Cap
$5,684,730,858.62
52W Range
$19.45 - $103.00
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
May 7, 2026 Q1
Market
EPS Estimate: $-0.9429
Revenue Estimate: $10,214,280.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Kymera Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Kymera Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Company Details
Market Cap
$7.16B
Shares Outstanding
78,949,032
Weighted Shares Outstanding
79,999,027
CEO
Nello Mainolfi
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
Employees
225
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Kymera Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...